UNSPSC 51111912: Temoporfin

This classification denotes a photosensitizing agent with the molecular formula C44H32N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FU21S769PF, chemically known as 3,3,3,3-(7,8-dihydroporphyrin-5,10,15,20-tetrayl)tetraphenol but generally known as temoporfin, which bears US NIH Compound Identifier 60751. European Medicines Agency schedules Temoporfin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10888MIG.

UNSPSC 51111912 Temoporfin is a Commodity code representing a photodynamic therapy pharmaceutical used in treatment protocols for certain cancers and precancerous conditions. State and local governments procure temoporfin primarily through health systems, hospital networks, and public health departments that operate oncology and dermatology services. The drug is typically sourced as part of broader pharmaceutical procurement or specialized therapeutic protocol acquisitions rather than as a standalone line-item buy, and appears in state Medicaid formulary management, public hospital cancer-center operations, and correctional-health pharmaceutical inventories where photodynamic therapy is offered.

The source provides no recent state and local contract opportunities tagged to this code. Temoporfin procurement at the state and local level is low-volume and highly specialized, typically embedded within larger pharmaceutical contracts, hospital oncology services agreements, or formulary management RFPs rather than standing as a discrete solicitation. Buying activity concentrates in states with large public hospital systems and comprehensive state Medicaid programs that fund photodynamic therapy protocols, but without recent posted opportunities in the source data, the geographic and issuing-body patterns cannot be characterized from current market activity.